

ANIKA THERAPEUTICS INC  
Form SC 13G/A  
November 22, 2013

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**SCHEDULE 13G**

**(Rule 13d-102)**

**Information Statement Pursuant to Rules 13d-1 and 13d-2**

**Under the Securities Exchange Act of 1934**

(Amendment No. 3)\*

**Anika Therapeutics Inc.**

(Name of Issuer)

Common Stock, par value \$0.01 per share

(Title of Class of Securities)

035255108

(CUSIP Number)

November 20, 2013

(Date of Event Which Requires Filing of This Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

\* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior page.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

---

CUSIP No. 035255108

NAMES OF REPORTING PERSONS

**1** Fidia Farmaceutici S.p.A.  
I.R.S. Identification Nos. of above  
persons (entities only)

CHECK THE APPROPRIATE BOX IF  
A MEMBER OF A GROUP (SEE  
INSTRUCTIONS)

**2** (a)   
(b)

SEC USE ONLY

**3**

CITIZENSHIP OR PLACE OF  
ORGANIZATION

**4**

Italy

SOLE VOTING POWER

**5**  
NUMBER OF None

SHARED VOTING POWER

**6**  
BENEFICIALLY OWNED BY None

SOLE DISPOSITIVE POWER

**7**  
EACH REPORTING PERSON None

SHARED DISPOSITIVE POWER

**8**  
WITH None

AGGREGATE AMOUNT  
BENEFICIALLY OWNED BY EACH  
REPORTING PERSON

**9**

None

**10** CHECK IF THE AGGREGATE  
AMOUNT IN ROW (9) EXCLUDES  
CERTAIN SHARES (SEE  
INSTRUCTIONS)

Not applicable

**11** PERCENT OF CLASS REPRESENTED  
BY AMOUNT IN ROW (9)

0%

**12** TYPE OF REPORTING PERSON (SEE  
INSTRUCTIONS)

CO (Corporation)

---

CUSIP No. 035255108

NAMES OF REPORTING PERSONS

**1** P&R S.p.A.  
I.R.S. Identification Nos. of above  
persons (entities only)

**2** CHECK THE APPROPRIATE BOX IF  
A MEMBER OF A GROUP (SEE  
INSTRUCTIONS)  
(a)   
(b)

**3** SEC USE ONLY

**4** CITIZENSHIP OR PLACE OF  
ORGANIZATION  
  
Italy

**5** SOLE VOTING POWER  
NUMBER OF  None

SHARES  SHARED VOTING POWER  
BENEFICIALLY **6**  
OWNED BY  None

EACH  SOLE DISPOSITIVE POWER  
REPORTING **7**  
PERSON  None

WITH  SHARED DISPOSITIVE POWER  
**8**  
 None

**9** AGGREGATE AMOUNT  
BENEFICIALLY OWNED BY EACH  
REPORTING PERSON

None

**10**

CHECK IF THE AGGREGATE  
AMOUNT IN ROW (9) EXCLUDES  
CERTAIN SHARES (SEE  
INSTRUCTIONS)

Not applicable

**11**

PERCENT OF CLASS REPRESENTED  
BY AMOUNT IN ROW (9)

0%

**12**

TYPE OF REPORTING PERSON (SEE  
INSTRUCTIONS)

CO

CUSIP No. 035255108

NAMES OF REPORTING PERSONS

**1** Fiore Holding S.r.l.  
I.R.S. Identification Nos. of above  
persons (entities only)

CHECK THE APPROPRIATE BOX IF  
A MEMBER OF A GROUP (SEE  
INSTRUCTIONS)

**2** (a)   
(b)

SEC USE ONLY

**3**

CITIZENSHIP OR PLACE OF  
ORGANIZATION

**4**

Italy

SOLE VOTING POWER

**5**  
NUMBER OF None

SHARED VOTING POWER

**6**  
BENEFICIALLY OWNED BY None

SOLE DISPOSITIVE POWER

**7**  
EACH REPORTING PERSON None

SHARED DISPOSITIVE POWER

**8**  
WITH None

AGGREGATE AMOUNT  
BENEFICIALLY OWNED BY EACH  
REPORTING PERSON

**9**

None

**10** CHECK IF THE AGGREGATE  
AMOUNT IN ROW (9) EXCLUDES  
CERTAIN SHARES (SEE  
INSTRUCTIONS)

Not applicable

**11** PERCENT OF CLASS REPRESENTED  
BY AMOUNT IN ROW (9)

0%

**12** TYPE OF REPORTING PERSON (SEE  
INSTRUCTIONS)

CO

Item 1(a). Name of Issuer

Anika Therapeutics, Inc., a Massachusetts corporation

**Item 1(b). Address of Issuer's Principal Executive Offices**

32 Wiggins Avenue, Bedford, MA 01730.

Item 2(a). Name of Person Filing

Item 2(b). Address of Principal Business Office or, if None, Residence

Item 2(c). Citizenship

Fidia Farmaceutici S.p.A.

Via Ponte della Fabbrica 3/A

Abano Terme (PD), Italy CAP 35031

Citizenship: Italy

P&R S.p.A.

Via Milano n. 186

Garbagnate Milanese (MI), Italy CAP 20024

Citizenship: Italy

Fiore Holding S.r.l.

Via Principe Amedeo n. 3

Milano (MI), Italy CAP 20121

Citizenship: Italy

Each of the foregoing is referred to as a “Reporting Person” and collectively as the “Reporting Persons”.

Item 2(d) Title of Class of Securities

Common Stock, \$0.01 par value per share.

Item 2(c) CUSIP No.

035255108

Item 3. If this Statement is Filed Pursuant to Rules 13d-1(b) or 13d-2(b) or (c), Check Whether the Person Filing is a:  
3. Not applicable

- (a) " Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).
- (b) " Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 73c).
- (c) " Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).
- (d) " Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
- (e) " An investment adviser in accordance with §13d-1(b)(1)(ii)(E).
- (f) " An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F).
- (g) " A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G).
- (h) " A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813).
- (i) .. A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3).
- (j) " Group, in accordance with §240.13d-1(b)(1)(ii)(J).

If filing as a non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J), please specify the type of institution:

\_\_\_\_\_

#### Item 4. Ownership

Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

(a) Amount beneficially owned:

None.

(b) Percent of class:

For each of the Reporting Persons: 0%.

(c) Number of shares as to which such person has:

(i) Sole power to vote or to direct the vote: None

(ii) Shared power to vote or to direct the vote: None

(iii) Sole power to dispose or to direct the disposition of: None

(iv) Shared power to dispose or to direct the disposition of: None

Item 5. Ownership of Five Percent or Less of a Class

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following x:

Item 6. Ownership of More Than Five Percent on Behalf of Another Person

Not applicable.

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person

Not applicable.

Item 8. Identification and Classification of Members of the Group

Not applicable.

Item 9. Notice of Dissolution of Group

Not applicable.

Item 10. Certifications

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.



**SIGNATURE**

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date: November 22, 2013

**FIDIA  
FARMACEUTICI S.P.A.**

/s/ Carlo Pizzocaro

By: Carlo Pizzocaro  
Title: Vice President

**P&R S.P.A.**

/s/ Francesco Pizzocaro

By: Francesco Pizzocaro  
Title: Chairman

**FIORE HOLDING  
S.R.L.**

/s/ Francesco Pizzocaro

By: Francesco Pizzocaro  
Title: Chairman

**Exhibit 1**

**JOINT FILING AGREEMENT**

In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a Statement on Schedule 13G and any amendments to it with respect to the Common Stock, par value \$0.01 per share, of Anika Therapeutics Inc., and further agree that this Joint Filing Agreement be included as an Exhibit to those joint filings.

Dated: November 22, 2013

**FIDIA  
FARMACEUTICI S.P.A.**

/s/ Carlo Pizzocaro

By: Carlo Pizzocaro  
Title: Vice President

**P&R S.P.A.**

/s/ Francesco Pizzocaro

By: Francesco Pizzocaro  
Title: Chairman

**FIGORE HOLDING  
S.R.L.**

/s/ Francesco Pizzocaro

By: Francesco Pizzocaro  
Title: Chairman